You are here

Advanced Tools for Mammalian Genome Engineering

Award Information
Agency: Department of Defense
Branch: Defense Advanced Research Projects Agency
Contract: D15PC00008
Agency Tracking Number: D2-1395
Amount: $999,350.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: ST13B-001
Solicitation Number: 2013.2
Solicitation Year: 2013
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-01-15
Award End Date (Contract End Date): 2017-01-14
Small Business Information
1419 Wilmington Island Road
Savannah, GA 31410
United States
DUNS: 000000000
HUBZone Owned: Yes
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 Amy Greene
 (218) 349-8749
Business Contact
 Amy Greene
Title: Dr.
Phone: (218) 349-8749
Research Institution
 The Corporation of Mercer University
 James Netherton
1400 Coleman Avenue
Macon, GA 31207
United States

 (478) 301-2710
 Nonprofit College or University

Recent advances in mammalian artificial chromosome design and engineering offer an alternative to existing methodologies for cellular bioengineering and address unmet needs to bioengineer more complex functionalities into human cells for subsequent commercialization. In this ST13B-001 application we propose to demonstrate utility of a novel chromosome-based gene delivery vehicle that is amenable to large genetic payloads while avoiding insertional mutagenesis and maintaining stable, long-term, gene expression. A cornerstone to our proposal is the utilization of a distinctive mammalian artificial chromosome technology termed Artificial Chromosome Expression System (ACE System), an autonomous chromosome-based circuit-board designed to contain approximately 70 site-specific recombination acceptor sites that can carry single or multiple copies of genes or DNA elements of interest. In Phase I of this solicitation we delivered a 144Kbp BAC containing the MCT1 genomic locus onto the platform ACE that had previously been loaded with a 168Kbp BAC, resulting in 312Kbp of total DNA added. In addition to demonstrating the specificity of integration we confirmed the structural stability of the genomic DNAs. In Phase II we will expand this disruptive technology by engineering additional robust and complex functionalities into the ACE system toward the goal of cell-based therapeutics.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government